Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059449 · ClinicalTrials.gov registry record
Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis
A clinical trial, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- 372
- Enrollment target
NCT00059449 is a clinical trial that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 372 participants.
The verdict
NCT00059449 has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- 372 participants
- Enrollment target
Study Summary
Necrotizing enterocolitis (NEC) is a serious gastrointestinal disorder that primarily affects preterm infants. About 10% of babies less than 32 weeks gestation at birth will develop it. Overall, 30% of babies who develop NEC will die from it, with many others developing long term gastrointestinal problems. The most important factor in its development is a premature intestinal tract. Epidermal growth factor (EGF) is an important growth factor in the development and maintenance of the gastrointestinal tract. This study will look for a relationship between EGF levels in premature babies and the development of NEC.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00059449
The ClinicalTrials.gov registry entry for NCT00059449 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00059449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00059449 about?
NCT00059449 is a clinical study titled "Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis". Necrotizing enterocolitis (NEC) is a serious gastrointestinal disorder that primarily affects preterm infants. About 10% of babies less than 32 weeks gestation at birth will develop it. Overall, 30% of babies who develop NEC will die from it, with many others developing long term gastrointestinal pr...
What is the current status of trial NCT00059449?
This trial is currently completed. The enrollment target is 372 participants.
Who is sponsoring clinical trial NCT00059449?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.